Latest information on COVID-19
Support teaching, research, and patient care.
Heike Elisabeth Daldrup-Link is a clinician-scientist in the Department of Radiology at Stanford University with subspecialisation in pediatric radiology, pediatric oncology imaging, and molecular imaging. Dr. Daldrup-Link trained at the University of Münster and the Technical University of Munich, Germany. She worked as an Assistant and Associate Professor at the University of California, San Francisco from 2003 to 2010, before joining Stanford Radiology in 2010. Her research interest focuses on the development of novel pediatric molecular imaging techniques, which interface observations of living cells with nanoparticle development and multimodality imaging technologies:Dr. Daldrup-Link developed several novel concepts for pediatric oncology imaging, such as tumor characterization through the EPR effect (US6009342-A), MR imaging of tumor associated inflammation with iron oxide nanoparticles (Clin Ca Res 2011 and 2018), image-guided cancer therapy without side effects through tumor-enzyme activated theranostic nanoparticles (Small 2014 and Molecular Oncology 2019) and radiation-free whole body staging of children with cancer (Lancet Oncology 2014 and Radiology 2020). Dr. Daldrup-Link’s cellular imaging studies also yielded several new and patented ideas for in vivo imaging of stem cell transplants establishing immediately clinically applicable technologies for: in vivo stem cell tracking with FDA-approved nanoparticles (US14/161,315), in vivo imaging of stem cell rejection processes with immune-cell targeted tracers, and MRI-detection of stem cell apoptosis with enzyme-activatable contrast agents (ACS Nano 2015) and iron oxide nanoparticle-enhanced MRI (Radiology 2019 and Theranostics 2020). Over the past 10 years, Dr. Daldrup-Link's team has received 77 honors and awards for innovative cellular imaging research.
As a physician-scientist involved in the care of pediatric patients and developing novel pediatric molecular imaging technologies, my goal is to link the fields of nanotechnology and medical imaging towards more efficient diagnoses and image-guided therapies. Our research team develops novel imaging techniques for improved cancer diagnosis, for image-guided-drug delivery and for in vivo monitoring of cell therapies in children and young adults. Over the past 15 years, our team successfully translated numerous new imaging technologies from preclinical research concepts to clinical applications, thereby creating direct value for our patients. Weblink: http://daldrup-link-lab.stanford.edu/
Pediatric PET/MR Image Registry
The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole
body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed
Tomography (CT) imaging for the diagnosis of tumors in children and young adults.
Sensitivities, specificities and diagnostic accuracies of the different imaging modalities
will be compared for significant differences.
View full details
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
The goal of the project is to evaluate osteonecrosis before and after decompression surgery
with ferumoxytol-enhanced MRI.
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with
ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors
to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help
in diagnosing patients correctly and may result in more timely treatment.
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
A research study on the diagnosis of spread of disease for children who have been diagnosed
with solid tumors using a new whole body imaging technique and a new MR contrast agent
(ferumoxytol). Standard tests that are used to determine the extent and possible spread of a
child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron
Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG)
scanning. The purpose of this study is to determine if newer imaging tests referred to as
whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of
the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The
advantage of the new imaging test is that it is associated with no or significantly reduced
radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole
body MR and PET/MR will be compared with that of the conventional, standard imaging studies
for tumor detecting.
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
The goal of this study is to develop a non-invasive imaging test for in vivo detection of
kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate
estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a
renal allograft on Ferumoxytol-MRI demonstrates significant differences between rejected and
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Sawyer, 650-302-2846.